| Medical and Health Sciences | 2021-2025 | 27 | KR 2 | 99.99 |
| Biological Sciences | 2021-2025 | 994 | KR 11 | 98.90 |
| Pulmonary and Respiratory Medicine | Lifetime | 71 | KR 2 | 99.90 |
| Oncology | Lifetime | 120 | KR 2 | 99.80 |
| Cancer Research | Lifetime | 810 | KR 4 | 94.10 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 3 | KR 1 | 99.98 |
| Oncology | 2021-2025 | 5 | KR 1 | 99.97 |
| Cancer Research | 2021-2025 | 93 | KR 1 | 95.85 |
| Molecular Biology | 2021-2025 | 901 | KR 13 | 94.95 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 498 | KR 15 | 89.68 |
| Immunology | 2021-2025 | 456 | KR 4 | 87.42 |
| Lung Cancer Research Studies | Lifetime | 26 | KR 2 | 99.82 |
| Lung Cancer Treatments and Mutations | Lifetime | 38 | KR 3 | 99.88 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 62 | KR 1 | 99.81 |
| Colorectal Cancer Treatments and Studies | Lifetime | 61 | KR 3 | 99.71 |
| Lung Cancer Diagnosis and Treatment | Lifetime | 79 | KR 5 | 99.70 |
| Gastric Cancer Management and Outcomes | Lifetime | 223 | KR 14 | 99.41 |
| Cancer therapeutics and mechanisms | Lifetime | 103 | KR 3 | 99.31 |
| Cancer Genomics and Diagnostics | Lifetime | 297 | KR 4 | 99.42 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 675 | KR 19 | 98.48 |
| Peptidase Inhibition and Analysis | Lifetime | 536 | KR 7 | 98.14 |
| HER2/EGFR in Cancer Research | Lifetime | 366 | KR 11 | 98.40 |
| Neuroendocrine Tumor Research Advances | Lifetime | 600 | KR 7 | 98.01 |
| Esophageal Cancer Research and Treatment | Lifetime | 451 | KR 7 | 97.58 |
| Colorectal and Anal Carcinomas | Lifetime | 505 | KR 25 | 97.05 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 584 | KR 7 | 95.77 |
| Brain Metastases and Treatment | Lifetime | 822 | KR 19 | 95.25 |
| Advanced Breast Cancer Therapies | Lifetime | 725 | KR 15 | 94.32 |
| Fibroblast Growth Factor Research | Lifetime | 961 | KR 13 | 90.02 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 2 | KR 1 | 99.98 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 9 | KR 1 | 99.94 |
| Lung Cancer Diagnosis and Treatment | 2021-2025 | 4 | KR 1 | 99.88 |
| Lung Cancer Research Studies | 2021-2025 | 3 | KR 1 | 99.96 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 5 | KR 1 | 99.90 |
| Cancer therapeutics and mechanisms | 2021-2025 | 2 | KR 1 | 99.75 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 19 | KR 3 | 99.76 |
| Cancer Genomics and Diagnostics | 2021-2025 | 33 | KR 1 | 99.62 |
| Peptidase Inhibition and Analysis | 2021-2025 | 23 | KR 3 | 99.36 |
| HER2/EGFR in Cancer Research | 2021-2025 | 57 | KR 4 | 99.02 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 479 | KR 26 | 96.40 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 504 | KR 8 | 92.99 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 738 | KR 19 | 88.54 |
| Advanced Breast Cancer Therapies | 2021-2025 | 626 | KR 17 | 88.48 |
| Cancer Research and Treatments | 2021-2025 | 559 | KR 12 | 83.60 |
| Chronic Myeloid Leukemia Treatments | 2021-2025 | 769 | KR 8 | 87.02 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 217 | KR 5 | 81.87 |
| Cancer Mechanisms and Therapy | 2021-2025 | 616 | KR 32 | 77.62 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 590 | KR 22 | 73.15 |
| Biochemical and Molecular Research | 2021-2025 | 834 | KR 8 | 63.57 |
| Protein Tyrosine Phosphatases | 2021-2025 | 545 | KR 14 | 52.95 |
| Chemical Reactions and Isotopes | 2021-2025 | 547 | KR 4 | 48.62 |
